Shionogi & Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shionogi & Co. Ltd.
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
The first-in-class, oral GPR35 agonist has shown preclinical promise as a potential treatment for gastrointestinal indications such as ulcerative colitis.
- OTC, Consumer
- Drug Discovery Tools
- Other Names / Subsidiaries
- Shionogi Healthcare Co., Ltd
- Shionogi Pharma Co., Ltd
- Shionogi Techno Advance Research Co., Ltd.
- Shionogi Administration Service Co., Ltd.
- Shionogi Business Partner Co., Ltd
- Shionogi Marketing Solutions Co., Ltd
- Shionogi Career Development Center Co., Ltd.
- Shionogi Digital Science Co., Ltd.
- Shionogi Pharmacovigilance Center Co., Ltd.
- Aburahi AgroResearch Co., Ltd.
- Shionogi Smile Heart Co., Ltd
- UMN Pharma Inc.
- Shionogi B.V.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.